Opinion|Videos|November 9, 2023

TROPION-Breast01: Dato-DXd in Metastatic HR+/HER2- Breast Cancer

Experts on breast cancer review recent data updates from TROPION-Breast01 on Dato-DXd (datopotamab deruxtecan) in metastatic HR+/HER2- breast cancer.


Latest CME